Home > Maligne hematologie > Lymfoïde ziekten > Plasmaceldyscrasieën > Multipel myeloom > Cartitude-6 (EMN28/68284528MMY3005)

Cartitude-6 (EMN28/68284528MMY3005)

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and examethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 24-6-2024, 21:16